[The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
The aim of study was the estimation of efficacy and safety of sevelamer treatment in children with chronic kidney disease with resistant hyperphsphatemia.


METHODS
The study group was 7 patients (hemodialysed--2 boys, mean age 7, 7+/-0.1; peritoneal dialysis--5: 3 boys and 2 girls, mean age 5, 6+/-5.0). Sevelamer (Renagel, 800 mg, Genzyme) was used in all patients in mean dosis of 117 mg/kgm.c./d due to lack of effect of the typical treatment (vitamin D, diet, calcium carbonate). Results of treatment by sevelamer were estimated by measuring of calcium, phosphates, albumins, parathormone and alkalic phosphate concentration in the serum and blood gases after 6 and 12 month.


RESULTS
There were found that sevelamer treatment significantly decrease the phosphates concentration and CaxP product in the serum without influence on concentration of PTH or calcium. Any adverse events were observed during the study and any drug intolerance.


CONCLUSIONS
Sevelamer treatment may be usefulness in children with resistant hyperphosphatemia.
Runowski
Dariusz
D
Department of Pediatrics, Nephrology and Toxicology, District Hospital in Szczecin. runko@wp.pl
Jachimiak
Bozena
B
Cieślak-Puchalska
Anna
A
Pacanowska
Beata
B
Zimoń
Tomasz
T
D002614:Chelating Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D010530:Peritoneal Dialysis / Q000009:adverse effects; D011073:Polyamines / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects; D000069603:Sevelamer; D016896:Treatment Outcome
D002614:Chelating Agents; D011073:Polyamines; D000069603:Sevelamer